November 20, 2025 — Leads & Copy — Conexeu Sciences Inc. has achieved a milestone in regenerative medicine by creating the first 3D-printed structures from its patented functional extracellular matrix (ECM).
The company’s patented CXU™ platform was used to print bovine-derived, collagen-based scaffolds that act like real tissue, building a base for personalized regeneration and moving regenerative medicine from repairing tissue to tissue on demand.
Dr. Claudia Chavez-Munoz, MD, PhD, Chief Science Officer of Conexeu, said the ability to print a functional, collagen-based extracellular matrix that behaves like the architecture of real tissue, as opposed to synthetic polymers or non-functional collagens, represents a new step for regenerative medicine. Data has shown that CXU™ is a material that the body recognizes as its own.
According to Dr. Chavez-Munoz, by showing that CXU™ can print tissue structures, Conexeu is opening the door to truly personalized implants and grafts that could be a game changer in the fields of aesthetics and tissue reconstruction. If, and when, cleared by the FDA, this will place CXU™ at the forefront of all bioinks, being the first collagen-based extracellular matrix medical grade in the market.
The development unlocks three high-value frontiers including:
- Personalized implants and grafts including craniofacial, breast, periodontal, and soft-tissue reconstruction, printed to match each patient.
- Vascular-supportive microenvironments in a functional matrix that supports neovascularization, which is critical for the long-term viability and function of cells.
- A single united platform for today’s clinic and tomorrow’s biofabrication. CXU™ now functions as both an injectable regenerative device and a printable ECM bioink, positioning the Company to enter the estimated $17.4B of addressable markets, which include wound care, aesthetics, dental, reconstructive surgery, and 3D bioprinting.
With the global bioprinting market projected to exceed $6B by 2032, Conexeu is positioned to become one of the foundational materials providers can access in a soon to be regenerative materials economy. 3D bioprinting enables us to create an implantable ECM that promotes vascularization just under the skin, supporting the long-term survival and function of cells.
Miles Harrison, President & CEO of Conexeu, said the future of medicine is not just repairing tissue, it is creating it. With CXU™, we can inject regeneration today, and we can design regeneration for tomorrow, Harrison said. This breakthrough prints with precision but lives like biology and it sets the stage for a completely new era of human reconstruction.
Key features of CXU™ Bioink include:
- Printable Collagen-based ECM: successfully demonstrated in 3D bio-printed constructs.
- Thermosensitive performance: liquid at room temperature, self-crosslinking to a gel at ~37°C in ~10 minutes.
- Biological integration: biomimetic ECM architecture that promotes natural healing, allowing vasculogenesis, cell migration and cell differentiation.
- Clinical relevance: designed to replicate a wound care device, Ten Minute Tissue™ has shown faster wound closure and reduced scarring in pre-clinical studies.
Conexeu’s Ten Minute Tissue™, the company’s first clinical product, is advancing toward its pre-510(k) submission targeted for Q3 2026, creating a clear commercial and regulatory path.
David Bogart can be reached at 1-424-333-5622 ext 7 or Ir@conexeu.com
Source: Conexeu Sciences Inc.
